Source: Annual Congress 2003 - Pulmonary disease in systemic disorders
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Müsellim, H. Ikitimur, I. Talasli, S. Erturan, G. Öngen (Istanbul, Turkey). 6 months treatment results of cyclophosphamide+prednisolone in scleroderma patients with lung involvement. Eur Respir J 2003; 22: Suppl. 45, 416

Member's Comments

No comment yet.

Related content which might interest you: Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 The effectiveness of plasmaferesis in patients with relapsing and progressing course of pulmonary sarcoidosis (5 years follow-up) Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Pulmonary sequelae in patients with COVID-19: results after 3 months of follow-up Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Neoplastic pericardial involvement as a first sign of lung cancer - diagnosis and treatment. An analysis of 33 patients treated in ICU Source: Eur Respir J 2002; 20: Suppl. 38, 76s Year: 2002 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Exercise capacity in patients with cystic fibrosis at 6 and 12 months after lung transplantation Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 One year follow-up of patients with idiopathic pulmonary fibrosis treated with immunosuppressive therapy Source: Annual Congress 2007 - Considerations in the management of idiopathic pulmonary fibrosis and other interstitial lung diseases Year: 2007 Two versus three months rehabilitation with the same number of sessions in patients with moderate to severe COPD: analysis of the results Source: Eur Respir J 2004; 24: Suppl. 48, 244s Year: 2004 The effect of prednisone treatment on lung function test parameters in patients with chronic sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 433s Year: 2002 The analysis of lung cancer patients (LCP) survival during 5 year period after diagnosis of disease Source: Eur Respir J 2006; 28: Suppl. 50, 88s Year: 2006 The effects of an 8 week pulmonary rehabilitation programme in patients with bronchiectasis Source: Annual Congress 2008 - Pulmonary rehabilitation for non-COPD and severe COPD; field exercise testing Year: 2008 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Effect of an 8 week pulmonary rehabilitation program in patients with interstitial lung diseases in India. Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 The long term results of surgical treatment of 297 patients with bullous lung emphysema Source: Eur Respir J 2007; 30: Suppl. 51, 561s Year: 2007 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Predictors of benefit persistence after 6 months from a pulmonary rehabilitation programme in moderate-severe COPD patients Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients Year: 2008 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008